Group 1 - The stock of Lai Kai Pharmaceutical-B (02105) rose over 4%, reaching HKD 19.94 with a trading volume of HKD 133 million [1] - The phase II study results of Eli Lilly's ActRIIA/B antibody Bimagurmab (Bima) in combination with semaglutide will be announced at the ADA conference on June 23 [1] - The agenda for the 2025 ADA conference includes a 90-minute session on Bima, featuring five presentations and discussions, focusing on the efficacy and safety comparison between Bima combined with semaglutide and semaglutide alone [1] Group 2 - Lai Kai Pharmaceutical's LAE102 will present its first human clinical data at the 2025 ADA conference, showcasing its potential alongside Bima [2] - Eli Lilly plays a crucial role in both Bima and LAE102, having acquired Bima and collaborating with Lai Kai Pharmaceutical for LAE102's phase I clinical study in the U.S. for obesity treatment, which began in late May and is expected to complete the main study phase by September 2025 [2]
港股异动 | 来凯医药-B(02105)午前涨超4% 将于ADA 2025大会上首次公布LAE102的人体临床数据